Sugi Predict

Sugi Predict / Compounds / SCHEMBL7263165

SCHEMBL7263165

SCHEMBL7263165

O=C(O)c1cc(O)ccc1Br

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.61
▸ CA1 P00915 3/20 0.61
▸ CA2 P00918 3/20 0.61
▸ CA7 P43166 3/20 0.61
▸ CA9 Q16790 3/20 0.61
▸ CA14 Q9ULX7 3/20 0.61
▸ ALOX5 P09917 1/20 0.61
▸ PTGS2 P35354 1/20 0.61
▸ TSHR P16473 2/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ HSD17B10 Q99714 2/20 0.53
▸ PTPN1 P18031 3/20 0.47
▸ MYC P01106 1/20 0.47
▸ AKR1C3 P42330 3/20 0.47
▸ AKR1C2 P52895 3/20 0.47
▸ AKR1C1 Q04828 3/20 0.47
▸ AKR1C4 P17516 2/20 0.47
▸ MEN1 O00255 3/20 0.46
▸ MAPT P10636 3/20 0.46
▸ KMT2A Q03164 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7065849 0.82 CA12 (0.61) CA12CA1CA2CA7CA9
SCHEMBL14978296 0.80 ALDH1A1 (0.46) CA12CA1CA2CA7CA9
SCHEMBL22423309 0.80 ERN1 (0.47) CA12CA1CA2CA7CA9
SCHEMBL570906 0.79 KDM4E (0.63) HSD17B10PTPN1MYCAKR1C3AKR1C2
SCHEMBL177949 0.78 ALDH1A1 (0.70) CA12CA1CA2CA7CA9
SCHEMBL31298798 0.78 ALDH1A1 (0.70) CA12CA1CA2CA7CA9
SCHEMBL6410064 0.78 CA12 (0.52) CA12CA1CA2CA7CA9
SCHEMBL9623284 0.78 MAOA (0.47) CA12CA1CA2CA7CA9
SCHEMBL8163290 0.77 KDM4E (0.61) HSD17B10PTPN1MYCAKR1C3AKR1C2
SCHEMBL70653 0.77 KDM4E (0.52) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3759087-B1 PROCESS-SCALE SYNTHESIS OF UROLITHIN A AMAZENTIS SA (CH) 2026-04-29 — — EP claimed
US-20260109681-A1 PROCESS-SCALE SYNTHESIS OF UROLITHIN A AMAZENTIS SA (CH) 2026-04-23 — — US claimed
US-12338224-B2 Process-scale synthesis of urolithin A AMAZENTIS SA (CH) 2025-06-24 — — US claimed
CN-119841800-A Method for preparing urolithin A by one-pot method 天津大学浙江研究院(绍兴) 2025-04-18 — — CN claimed
CN-119504691-A 8-Hydroxy urolithin A derivative and preparation method and application thereof 常州大学 2025-02-25 — — CN claimed
CN-118955276-A Preparation method of 2-bromo-5-hydroxybenzoic acid 舞阳威森生物医药有限公司 2024-11-15 — — CN claimed
US-20230357176-A1 PROCESS-SCALE SYNTHESIS OF UROLITHIN A PATHEON AUSTRIA GMBH & CO KG (AT) 2023-11-09 — — US claimed
US-11634401-B2 Process-scale synthesis of urolithin A AMAZENTIS SA (CH) 2023-04-25 — — US claimed
US-20210198225-A1 PROCESS-SCALE SYNTHESIS OF UROLITHIN A PATHEON AUSTRIA GMBH & CO KG (AT) 2021-07-01 — — US claimed
US-10906883-B2 Process-scale synthesis of urolithin A AMAZENTIS SA (CH) 2021-02-02 — — US claimed
EP-3759087-A1 PROCESS-SCALE SYNTHESIS OF UROLITHIN A Amazentis SA (CH) 2021-01-06 — — EP claimed
CN-112074510-A Industrial-Scale Synthesis of urolithin A 阿马曾提斯公司 2020-12-11 — — CN claimed
US-20190263772-A1 PROCESS-SCALE SYNTHESIS OF UROLITHIN A PATHEON AUSTRIA GMBH & CO KG (AT) 2019-08-29 — — US claimed
EP-3756664-B1 OSTEOCLAST DIFFERENTIATION INHIBITOR CONTAINING UROLITHIN DAICEL CORP (JP) 2026-05-20 — — EP disclosed
EP-3759087-B1 PROCESS-SCALE SYNTHESIS OF UROLITHIN A AMAZENTIS SA (CH) 2026-04-29 — — EP disclosed
US-20260109681-A1 PROCESS-SCALE SYNTHESIS OF UROLITHIN A AMAZENTIS SA (CH) 2026-04-23 — — US disclosed
EP-0745595-A1 3-(3-Aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents American Cyanamid Company (US) 1996-12-04 — — EP disclosed
US-5519133-A CYCLIZATION, ALKYLATION AMERICAN CYANAMID CO. (US) 1996-05-21 — — US disclosed
EP-0659047-A1 HERBICIDAL BENZENE COMPOUNDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1995-06-28 — — EP disclosed
WO-1994005153-A1 HERBICIDAL BENZENE COMPOUNDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1994-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10906883-B2 Process-scale synthesis of urolithin A UROD, UMPS, UTS2R CA12 708/4885CA1 1469/4885CA2 1536/4885
US-12338224-B2 Process-scale synthesis of urolithin A UTS2R, RUVBL2, UROD CA12 431/4885CA1 664/4885CA2 371/4885
US-20210198225-A1 PROCESS-SCALE SYNTHESIS OF UROLITHIN A UROD, UMPS, UTS2R CA12 708/4885CA1 1469/4885CA2 1536/4885
US-20230357176-A1 PROCESS-SCALE SYNTHESIS OF UROLITHIN A UROD, UMPS, UTS2R CA12 708/4885CA1 1469/4885CA2 1536/4885
US-20260109681-A1 PROCESS-SCALE SYNTHESIS OF UROLITHIN A UQCRC2, MCU, UQCRC1 CA12 2083/4885CA1 3185/4885CA2 499/4885
US-20190263772-A1 PROCESS-SCALE SYNTHESIS OF UROLITHIN A UROD, UMPS, UTS2R CA12 708/4885CA1 1469/4885CA2 1536/4885
US-11634401-B2 Process-scale synthesis of urolithin A UROD, UMPS, UTS2R CA12 708/4885CA1 1469/4885CA2 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.